fda warning letters glp-1 november 2025 🚨 Moves to Permanently Shut Down Compounded GLP-1s The FDA is taking steps to eliminate large-scale compounding of medications like semaglutide and tirzepatide, signaling a major shift in how these February 17, 2026: Pennsylvania compounding

Finally, medications whose CVOTs result in the upper bound falling below 1.3 may be approved without the need for further documentation of CV safety in post-marketing studies ( Figure 3 )

Who should not take spirulina

Emerging research suggests that GLP-1RAs may also be beneficial in treating conditions like obstructive sleep apnea (Malhotra et al., 2024), osteoarthritis (Bliddal et al., 2024), metabolic dysfunction-associated steatotic liver disease (MASLD) and steatohepatitis with liver fibrosis (MASH) (Loomba et al., 2024), polycystic ovary syndrome (PCOS) (Szczesnowicz et al., 2023), Alzheimers disease (Liang et al., 2024), Parkinsons disease (Kalinderi et al., 2024), and addiction (Klausen et al., 2022)

GLP-1, semaglutide, oral Rybelsus mimics a gut hormone called GLP-1 (glucagon-like peptide-1)